A Phase II Clinical Trial of Single Agent Pembrolizumab in Subjects with Advanced Adrenocortical Carcinoma
The adrenal glands sit atop the kidneys and produce important hormones. Cancer in the outer layer of an adrenal gland is rare and is called adrenocortical carcinoma. In this study, researchers are evaluating the safety and effectiveness of the drug pembrolizumab in patients with advanced adrenocortical carcinoma.
Pembrolizumab is a form of immunotherapy. It works by blocking a molecule called PD-1 that shuts down the immune response. Blocking PD-1 can allow the immune system to detect and attack cancer cells. Pembrolizumab is already approved to treat melanoma and non-small cell lung cancer; its use in this study is considered investigational. It is given intravenously (by vein).
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have inoperable or metastatic adrenocortical carcinoma that cannot be cured with local therapies.
- Patients must recover from the serious side effects of any prior treatments before entering the study.
- Patients must be physically well enough that they are fully ambulatory, capable of all self care, and are capable of all but physically strenuous activities. As an example, patients must be well enough that they would be able to carry out office work or light housework.
- This study is for patients age 18 and older.
For more information about this study and to inquire about eligibility, please contact Dr. Diane Reidy-Lagunes at 646-888-4185.